Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety profile and the maximum dose of Debio
1143 (AT-406) that can be given to humans. This study is also designed to measure how much
Debio 1143 (AT-406) gets into the blood stream (pharmacokinetics), and how Debio 1143
(AT-406) interacts with proteins related to cancer that the drug is targeted to affect
(pharmacodynamics).